Oxis looking to enter cannabis biotech sector

11 August 2014

USA-based Oxis International, currently working on products around the effects of oxidative stress, is looking to take advantage of the changing medical marijuana laws coming into force through America by changing the direction of business towards cannabis-related therapies.

Oxis is currently in discussion to license certain intellectual property from current leaders in the cannabis biotech space. The company has recently completed financing of $1.425 million to bring its required Securities and Exchange Commission (SEC) filings to current status, increase marketing of Oxis nutraceutical products and investigate possible business acquisitions in the nutraceutical and marijuana sectors.

Directors Anshuman Dube and David Saloff have resigned from the board of directors as part of the change of direction.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK